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Magnetic resonance imaging examinations are frequently carried out using contrast agents to improve the image quality.
Practically all clinically used contrast agents are based on paramagnetic metals and lack in selectivity and specicity. A group
of stable organic radicals, nitroxides, has raised interest as new metal-free contrast agents for MRI. eir structures can easily
be modied to incorporate dierent functionalities. In the present study, a stable nitroxide TEEPO (2,2,6,6-tetraethylpi-
peridin-1-oxyl) was linked to a glucose moiety (Glc) to construct a water-soluble, potentially tumor-targeting compound with
contrast-enhancing ability. e ability was assessed with in vivoMRI experiments. e constructed TEEPO-Glc agent proved
to shorten the T1 relaxation time in tumor, while the T1 time in healthy brain tissue remained the same.e results indicate the
potential of TEEPO-Glc as a valuable addition to the growing eld of metal-free contrast enhancement in MRI-
based diagnostics.
1. Introduction
Magnetic resonance imaging (MRI) is one of the most
prominent imaging modalities due to its superior versatility,
soft tissue contrast, and resolution. Although optimizing
imaging conditions often leads to excellent image quality, in
some cases, the contrast between pathologies and healthy
tissue is improved by utilizing contrast agents (CAs).
Contrast agents can also increase the signal-to-noise ratio
(SNR) leading to better image quality and resolution. Tra-
ditional contrast agents are mainly based on a paramagnetic
gadolinium metal due to its seven unpaired electrons, high
magnetic moment, and long electron spin relaxation [1, 2].
However, free Gd3+ is toxic in human body mainly due to its
identical ionic size with Ca2+. As a result, it can potentially
bind to Ca2+ channels and disturb protein synthesis [3].
erefore, gadolinium is tightly bound with organic ligands,
increasing both its kinetic inertness and thermodynamic
stability [2]. In 2006, it was reported that the use of gado-
linium-based contrast agents (GBCAs) on patients with
renal impairment could cause nephrogenic systemic brosis
(NSF) [4]. Later on, the prevalence of NSF was linked with
the use of less stable, linear contrast agents. With thorough
patient screening and restricted use of certain GBCAs, their
use has been generally considered safe. Until 2015, it was
prevailed that with patients going through several scans with
GBCAs, gadolinium can deposit in brain [5]. Although the
retention of gadolinium has not been found to be harmful
for patients, the European Medical Agency (EMA) recom-
mended suspension or restricted the use of four linear
GBCAs [6]. Another concerning aspect, due to the broad use
of GBCAs, is the ndings of anthropogenic gadolinium in
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aquatic environments [7] and even in drinking water [8].
erefore, the development of new, metal-free contrast
agents has accelerated.
Two general approaches to avoid the use of metals in CAs
are the exploitation of chemical exchange saturation transfer
(CEST) [9, 10] or hyperpolarized [11–13]MRI contrast agents.
However, these methods are quite complex and often require
special techniques or dedicated hardware, which often causes
some restrictions to their clinical applicability. Lately, a group
of contrast agents based on paramagnetic stable radicals,
nitroxides, has emerged.e applicability of nitroxides inMRI
was discovered already in the 1980s [14]. Nitroxide radicals
have a wide range of applications in organic synthesis [15, 16],
radical polymerization [17], spin labelling [18], as molecular
magnets [19], and organic batteries [20–22]. Nitroxides are
often prone to reduction by various natural reductants such as
ascorbic acid or enzymes, which leads to formation of their
diamagnetic equivalents, hydroxylamines. However, nitro-
xides with bulky side groups have shown remarkable stability
in conditions mimicking biological matrix [23, 24]. e re-
search of nitroxide-based contrast agents comprises both
macromolecular [25–31] and small molecule [32–36] systems.
It is often considered that the advantage of using polymers or
nanomaterials as a backbone for nitroxides is the possibility to
attach several radical centers to the contrast agent molecule.
Also, large molecules often have long rotational correlation
times indicating their tumbling rates, which increases the
relaxivity of the contrast agent [25]. However, increasing the
size of the contrast agent molecule also has unfavorable eects
on tissue penetration and delivery [2].
Our study has focused on attaching a highly stable
nitroxide, TEEPO (2,2,6,6-tetraethylpiperidin-1-oxyl), to
natural compound moieties that can potentially act as tar-
geting units [35, 36].emethod is commonly applied in the
use of radiopharmaceuticals as tracers in PET (positron
emission tomography) imaging [37]. In our rst study, we
presented the synthesis of TEEPO-Glc (Figure 1), where
TEEPO is covalently attached to a glucose molecule [35].
One of the main advances of using glucose is its ability to
increase the water solubility of the otherwise lipophilic
TEEPO. Our study presented superior stability of the
compound in a matrix mimicking biological environment
and against a natural reductant ascorbic acid. It also dis-
played a preliminary study on its cytotoxicity and relaxation
enhancement properties in in vitro NMR and phantomMRI
experiments. Herein, we present the results of a more de-
tailed in vitro cytotoxicity study and also the relaxation
enhancing properties with in vivo MRI experiments.
2. Materials and Methods
2.1. In Vitro Cytotoxicity Study. e preparation of the
TEEPO-Glc contrast agent as well as the cell viability study
with HeLa cells is described in earlier publication [35]. For the
in vitro cytotoxicity studies, HeLa cells were cultured in a
complete cell culture medium composed of Dulbecco’s
modied Eagle’s medium (DMEM, Sigma-Aldrich, UK), 10%
heat-inactivated fetal bovine serum (Gibco, Life Technologies/
ermo Fisher Scientic, US), penicillin (100U/ml), and
streptomycin (100μg/ml) (Gibco, Life Technologies/ermo
Fisher Scientic, US). e cells were maintained in standard
cell culture conditions (37°C, 5% CO2 and 95% humidity) in a
Sanyo MCO-18AIC CO2 incubator (Sanyo Electric, Osaka,
Japan). e HUVECs (human umbilical vein endothelial cells;
Lonza) were grown on 0.1% gelatin-coated 100mmcell culture
dishes and passage numbers from P8 to P9 were used for the
experiments.e cells were maintained in a complete medium
containing M199 (Gibco, Life Technologies/ermo Fisher
Scientic, US), 15% fetal bovine serum, heparin (5 units/ml)
(Sigma-Aldrich, UK), endothelial cell growth factor (20μg/ml)
(ECGF, Roche Biomolecules, Switzerland), 1% L-glutamine,
1% streptomycin, and 1% penicillin, in a 5% CO2 incubator at
37°C.
To study the cell viability with HUVECs, the cells (10,000
cells per well) were seeded on 0.1% gelatin-coated white 96-
well tissue culture plates, and they were allowed to attach for
24 h. After two washes with phosphate-buered saline (PBS)
(200 μl per well), the cells were treated with TEEPO-Glc (0.2,
1, and 10mM in culture medium) for 1, 6, and 24 h. e cell
viability was measured using the CellTiter-Glo® reagent(Promega, US) with a Fluoroskan Ascent FL (ermo
Labsystems, US) luminometer according to the manufac-
turer’s instructions. For the LDH release assay, HeLa cells
(10,000 cells per well) were seeded on 96-well tissue culture
plates (Corning Inc., Corning, NY, US) and HUVECs
(10,000 cells per well) on 0.1% gelatin-coated 96-well tissue
culture plates.ey were allowed to attach for 24 h. After two
washes with PBS (200 μl per well), cells were treated with
TEEPO-Glc (0.2, 1, and 10mM in culture medium) for 1, 6,
and 24 h. After exposure, the release of LDH was monitored
from an aliquot of 50 μl of the supernatant using
CytoTox96® Nonradioactive Cytotoxicity assay (Promega,US) according to the manufacturer’s instructions. e ab-
sorbance was determined with a Bio-Rad microplate reader
(model-550) (Bio-Rad, US) at a wavelength of 490 nm. e
release of LDH in untreated cells was used as a control. e
cells lysed with the lysis solution provided in the LDH assay
kit were used as a positive control and set at 100% LDH
release. Statistical analysis was performed by Kruskal–Wallis
with Dunnett’s test. Dierences were considered signicant
when p< 0.05.
2.2. In Vivo Experiments. C6 glioma cells (ECACC/Sigma-
Aldrich, UK) were grown in a 10 cm Petri dish in 10ml of
high-glucose Dulbecco’s modied eagle medium (DMEM,
Sigma-Aldrich, UK) supplemented with 10% fetal bovine
serum and 1% penicillin-streptomycin at 37°C in the
presence of 5% CO2. Upon reaching approximately 80%
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Figure 1: e structure of the contrast agent TEEPO-Glc.
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conﬂuence, the cells were washed twice with PBS and
trypsinised with 1ml of 0.4% trypsin solution.
All animal experiments were approved by the Animal
Health Welfare and Ethics Committee of University of
Eastern Finland. Female Wistar rats (n � 11, 190–380 g,
Envigo, UK) were anesthetized with intraperitoneal (i.p.)
injection of ketamine 60mg/kg (Ketalar vet 50mg/ml,
Pﬁzer, US) and medetomidine hydrochloride 0.4mg/kg
(Domitor vet 1mg/ml, Orion Pharma Animal Health,
Finland). C6 cells (1× 106 C6 cells per 10 μl of ice-cold PBS)
were implanted to stereotactic coordinates of 1mm caudal
from bregma, 2mm to the right of the sagittal suture, and
2mm below the top of bregma through a burr hole. Animals
received postoperation pain medication (Norocarp, Vet
Medic Pharmaceuticals Oy, Finland) after surgery.
MRI experiments were performed using a 9.4 T hori-
zontal magnet interfaced to Agilent (Santa Clara, US) im-
aging console and a volume coil transmitter/4-channel
surface coil receiver pair (Rapid Biomedical, Rimpar, Ger-
many) on days 7–14 postsurgery. During the experiments,
the animals were anesthetized with isoﬂurane (5% induction,
1-2% upkeep, 70 : 30 N2 : O2 gas mixture at 2 L/min) and
placed inside a holder with breath monitoring (60–80
breaths per minute) and temperature control (37°C) using
warm water. Axial multislice MRI data covering the tumor
and normal brain were ﬁrst collected. T1 (inversion-recovery
FLASH (Fast LowAngle SHot), 12 inversion times between 5
and 5500ms, 10 s delay between inversions, TR within
FLASH 7.8ms, TE 3.9ms, 10° ﬂip angle, 32× 32mm2 FOV,
128× 64 data matrix, and twelve 1mm slices) and T2 (multi
spin-echo with 16 echoes collected between 8.1 and
129.8ms, TR 2 s, 32× 32mm2 FOV, 128× 64 data matrix,
and eight 1mm slices) maps were collected before CA in-
jection and for up to one hour after injection. Fast gradient
echo multislice imaging (TR 156ms, TE 4.5ms, ﬂip angle
90°, 32× 32mm2 FOV, 256×128 data matrix, and eight
1mm slices) was performed during CA injection; imaging
started 1min before the start of the injection and continued
for 10mins after the injection. For TEEPO-Glc, the ﬁnal
concentration was 0.5 to 2.2mmol/kg (injection volume was
6ml/kg with sample concentration varying between 75 and
277mM) (n � 7). For Gd(DTPA) (gadopentetate dimeglu-
mine), ﬁnal concentration was 0.1mmol/kg (injection vol-
ume 1ml/kg with 100mM sample concentration; n � 4; one
of the animals had received injection of TEEPO-Glc ap-
proximately 70 minutes before Gd(DTPA) injection. Addi-
tionally, 4-hydroxy-TEMPO (2,2,6,6-tetramethylpiperidin-1-
oxyl) at concentration 1.6mmol/kg was injected (injection
volume ∼6ml/kg, concentration 290mM; n � 2; one of the
animals received a Gd(DTPA) injection 60 minutes later). All
data were analyzed in Matlab (Mathworks, Natick,
US). Parameter maps were calculated using monoexponential
ﬁts.
3. Results and Discussion
3.1. Toxicity Eﬀects of TEEPO-Glc inHeLaCells andHUVECs.
To study the in vitro cytotoxicity of TEEPO-Glc, a set of cell
viability and LDH release tests were performed in HeLa cells
[35] and primary human endothelial cells, HUVECs. Dif-
ferent concentrations of TEEPO-Glc (0.2, 1, and 10mM)
were incubated for 1, 6, and 24 h. .e cytotoxicity was
studied using cell viability assay (Figures 2(a) and 2(b)) and
LDH (lactate dehydrogenase) release assay (Figures 2(c) and
2(d)). .e cell viability assay is based on quantitation of ATP
(adenosine triphosphate), the amount of ATP being directly
proportional to the number of living cells. .e LDH release
assay is a colorimetric assay for the measurement of cyto-
plasmic LDH enzyme activity present in all cells. LDH is
released rapidly from the cytosol into culture medium upon
the damage of plasma membranes of the cells.
As our earlier results showed, at a high concentration of
TEEPO-Glc (10mM) and with long incubation time (24 h),
the cellular viability (p< 0.05) of HeLa cells decreased sig-
niﬁcantly compared with unexposed controls (Figure 2(a)).
With lower concentrations (0.2mM and 1mM) or shorter
incubation times (1 h and 6h) TEEPO-Glc showed no eﬀect on
the cell viability. For HUVECs, TEEPO-Glc caused a signif-
icant reduction in cellular viability at a concentration of
10mM at all detected time points, 1 h, 6 h, and 24h (p< 0.05)
(Figure 2(b)). However, lower concentrations of TEEPO-Glc
(0.2mM or 1mM) did not have an eﬀect on the cell viability.
Concomitantly, results from LDH assay showed that none of
the TEEPO-Glc treatments (0.2, 1, or 10mM) caused sig-
niﬁcant membrane damage for the cultured HeLa cells
(Figure 2(c)), albeit there is a slight increase with the highest
concentration (10mM) with 24 h incubation time. With
HUVECs, the 10mM concentration induced a signiﬁcant
LDH release (p< 0.05) and loss of plasmamembrane integrity
at all tested time points (1, 6, and 24 h) compared with un-
treated control cells (Figure 2(d)). Lower concentrations of
TEEPO-Glc did not show anymembrane-damaging eﬀects for
HUVECs at any time points tested. All in all, the TEEPO-Glc
contrast agent showed toxicity only at a high 10mM con-
centration and can be considered scarcely toxic in concen-
trations relevant to practical use.
3.2. Relaxation Enhancement Studies with In Vivo MRI.
.e relaxation-enhancing properties of TEEPO-Glc were
assessed with an in vivo MRI study. In the study, T1 maps
were collected before, during, and after contrast agent in-
jection with an inversion-recovery FLASH imaging se-
quence..emaps were recorded using both TEEPO-Glc and
Gd(DTPA) (gadopentetate dimeglumine) as contrast agents
in order to compare the results of TEEPO-Glc to a common
GBCA. Figure 3 presents the T1 results of a representative
animal. Figure 3(a) displays the T1 images of the rat brain at
approximately 10 minute intervals starting from the in-
jection of contrast agent and T1 times with respect to the
time after the injection. After 60 minutes of the TEEPO-Glc
injection, the animal received the Gd(DTPA) injection. .e
T1 values were determined both in tumor and in normal,
healthy brain. .eir regions of interest (ROI) are outlined in
red and blue, respectively, in Figure 3(a). Figure 3(b) displays
the average T1 relaxation times within ROI with respect to
the time, and the error bands represent the standard de-
viation (±SD) within ROI..e diﬀerences in the preinjection
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T1 times between tumor and normal brain area arise from
the existing contrast between healthy and malignant tissue.
e results display a clear drop in the T1 relaxation time in
tumor after the TEEPO-Glc injection. e eect was at
strongest between 10 and 15 minutes after the injection
resulting in a decrease of approximately 20% in T1. After 50
minutes, the T1 value had returned back to the level of
preinjection T1 relaxation time. Judging from the high
stability of TEEPO-Glc, this is most likely due to the contrast
agent clearance instead of bioreduction [35]. In the healthy
brain, no decrease in the T1 times was detected. Regarding
the accumulation and retention time, TEEPO-Glc showed
similar behaviour to Gd(DTPA) in the experiments, albeit
the relaxation eect is much higher with Gd(DTPA)
(Figure 3). e compared T1 decreases in tumor are also in
accordance with the r1 relaxivity values determined for the
compounds in vitro.e r1 of TEEPO-Glc was determined to
be 0.13mM− 1 s− 1 in 9.4 T which is similar to the values
calculated from the earlier in vitro NMR and phantom MRI
studies (0.12mM− 1 s− 1 in 11.7 T and 0.23mM− 1 s− 1 in 1.5 T
eld) [35]. e r1 value of Gd(DTPA) is signicantly higher,
4mM− 1 s− 1 [38], which can be observed as a stronger de-
crease in the T1 time after the Gd(DTPA) injection. e
higher relaxivity of Gd(DTPA) is supposedly due to the fact
that gadolinium has seven unpaired electrons, whereas
TEEPO-Glc has one unpaired electron. Additionally, with
Gd(DTPA), the relaxation enhancement is the result of both
inner- and outer-sphere relaxation. Inner-sphere relaxation
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Figure 2: TEEPO-Glc cytotoxicity in vitro. Cell viability study with (a) HeLa cells (reproduced from Ref. 35 with permission frome Royal
Society of Chemistry) and (b) HUVECs were determined by CellTiter-Glo® assay kit (ATP measurement), and the results (mean± SD,
n  4) were compared with untreated control cells whose viability was set at 100%. LDH release study with (c) HeLa cells and (d) HUVECs.
Control cells were lysed with LDH assay lysis solution and set at 100% (lysis). e level of signicance was set at a probability of p< 0.05 (∗)
when compared with untreated control cells (Kruskal–Wallis with Dunnett’s test).
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is caused by the water molecule directly coordinating to the
paramagnetic center, and outer-sphere relaxation is a result
of water molecules diusing close to the contrast agent
molecule [1, 2]. With TEEPO-Glc, only the outer-sphere
relaxation is relevant as there is no direct bond between the
water molecule and the nitroxide. e T2 values in tumor
were not aected by TEEPO-Glc even though it showed a
good contrast in the previous phantom study. Similar to
GBCAs, nitroxides seem to shorten both T1 and T2 times, but
the relative eect in tissue is much smaller for T2 than for T1
making them primarily T1 contrast agents [1].
Concentration of TEEPO-Glc was varied across the ex-
periments to assess the eect of dose on the apparent CA
concentration in the tumor. e relative concentrations were
calculated from the relaxation rates (R1 1/T1) and the r1
values (0.13mM− 1 s− 1 for TEEPO-Glc and 4mM− 1 s− 1 for
Gd(DTPA)). e apparent maximal tumor concentrations
measured at ∼10mins after injection for both compounds are
shown in Table 1. Although lower apparent concentration was
observed at the lowest injected dose (0.5mmol/kg), the higher
TEEPO-Glc doses all showed relatively similar apparent tumor
concentrations.e concentrations have also been normalized
to the injected dose (μmol) to derive an approximate %ID/g
value (percent of injected dose per gram of tissue) (Table 1).
e apparent %ID/g were 0.19± 0.09 and 0.25± 0.09, for
TEEPO-Glc and Gd(DTPA), respectively. is implies similar
initial uptake of the two contrast agents despite dierent
concentrations. e underlined animal (animal 3) received
both TEEPO-Glc and Gd(DTPA) injection (see Table 1).
e apparent contrast agent concentrations in the tumor
ROI are presented with respect to postinjection time in
Figure 4. e %ID/g is presented as an average of all the
animals listed in Table 1. e loss of TEEPO-Glc contrast
was faster than Gd(DTPA) (p< 0.01, Student’s t-test, Fig-
ure 4), with amean lifetime of 23± 8min and 49± 10min for
TEEPO-Glc and Gd(DTPA), respectively. Together the
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Figure 3: T1 mapping was performed with inversion-recovery FLASH in 9.4 Tmagnetic eld. (a) T1 images measured before the injection
(left) and approximately every 10 minutes after the injection.e red and blue areas indicate the tumor and normal brain regions of interest
(ROI), respectively. (b) e corresponding T1 relaxation times in tumor and healthy brain as a function of time with error bands (± SD).
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results on apparent TEEPO-Glc concentration in tumor and
the fast elimination indicate low targeting eect. Conse-
quently, we were interested in looking into the accumulation
and relaxation enhancing properties of the radical moiety
without the glucose unit. However, the nitroxide radical, 4-
hydroxy-TEEPO, is highly lipophilic and consequently in-
soluble in either pure saline or saline doped with 10%DMSO
or TWEEN20/80 at desired concentrations and could not act
as a reference to review the targeting eect of the glucose
unit. Additionally, 4-hydroxy-TEMPO (2,2,6,6-tetrame-
thylpiperidin-1-oxyl) was soluble in saline doped with
DMSO but did not show any change in T1 relaxation times at
10 minutes, suggesting it underwent rapid bioreduction and
lost its paramagnetism ruling it out as a reference.
4. Conclusions
As a conclusion, we have developed a fully organic, stable,
and water-soluble compound with the ability to enhance
relaxation in MRI. e compound displayed similar be-
havior to an existing MRI contrast agent, Gd(DTPA),
concerning accumulation and retention in the tumor area.
Unfortunately, the targeting eects could not be conrmed
with this study. Also, due to the low relaxivity of the
compound, it is an unlikely candidate to replace the existing
contrast agents as such. However, this compound could be
expected to bring an addition to the established MRI di-
agnostics by opening new ways to study the growing group
of metal-free contrast agents for MRI.
Table 1: Apparent tumor CA concentration in each animal.
Animal Injected dose (μmol/g) Injected dose (μmol) Apparent tumor concentration (mM∼μmol/g) %ID/g
TEEPO-Glc
1 2.2 693 0.67 0.10
2 1.6 615 0.85 0.14
3 1.2 385 0.83 0.22
4 1.2 285 0.59 0.21
5 1.0 206 0.65 0.32
6 1.0 210 0.48 0.23
7 0.5 105 0.09 0.09
Average 0.19± 0.08
Gd(DTPA)
3 0.1 34 0.12 0.37
8 0.1 37 0.05 0.15
9 0.1 37 0.09 0.24
10 0.1 33 0.09 0.27
Average 0.25± 0.09
0 10 20 30 40 50 60
Time postinjection (min)
0.05
0.1
0.15
0.2
0.25
0.3
0.35
%
ID
/g
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Figure 4: Apparent CA concentrations of TEEPO-Glc and Gd(DTPA) as a function of time postinjection. TEEPO-Glc was disappearing
from tumor at a faster rate than Gd-DTPA.
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